Glycoproteomics in Neurodegenerative Diseases

Overview

Journal Mass Spectrom Rev

Publisher Wiley

Specialty Chemistry

Date 2009 Apr 10

PMID 19358229

Citations 45

Authors

HyeJin Hwang

Jianpeng Zhang

Kathryn A Chung

James B Leverenz

Cyrus P Zabetian

Elaine R Peskind

Joseph Jankovic

Zhen Su

Aneeka M Hancock

Catherine Pan

Thomas J Montine

Sheng Pan

John Nutt

Roger Albin

Marla Gearing

Richard P Beyer

Min Shi

Jing Zhang

Affiliations

Soon will be listed here.

Abstract

Protein glycosylation regulates protein function and cellular distribution. Additionally, aberrant protein glycosylations have been recognized to play major roles in human disorders, including neurodegenerative diseases. Glycoproteomics, a branch of proteomics that catalogs and quantifies glycoproteins, provides a powerful means to systematically profile the glycopeptides or glycoproteins of a complex mixture that are highly enriched in body fluids, and therefore, carry great potential to be diagnostic and/or prognostic markers. Application of this mass spectrometry-based technology to the study of neurodegenerative disorders (e.g., Alzheimer's disease and Parkinson's disease) is relatively new, and is expected to provide insight into the biochemical pathogenesis of neurodegeneration, as well as biomarker discovery. In this review, we have summarized the current understanding of glycoproteins in biology and neurodegenerative disease, and have discussed existing proteomic technologies that are utilized to characterize glycoproteins. Some of the ongoing studies, where glycoproteins isolated from cerebrospinal fluid and human brain are being characterized in Parkinson's disease at different stages versus controls, are presented, along with future applications of targeted validation of brain specific glycoproteins in body fluids.

Citing Articles

Complementary Strategies to Identify Differentially Expressed Genes in the Choroid Plexus of Patients with Progressive Multiple Sclerosis.

Rodrigues A, Passetti F, Guimaraes A Neuroinformatics. 2025; 23(2):10.

PMID: 39836313 DOI: 10.1007/s12021-024-09713-2.

LeGenD: determining N-glycoprofiles using an explainable AI-leveraged model with lectin profiling.

Li H, Peralta A, Schoffelen S, Hansen A, Arnsdorf J, Schinn S bioRxiv. 2024; .

PMID: 38585977 PMC: 10996628. DOI: 10.1101/2024.03.27.587044.

Blood-based CNS regionally and neuronally enriched extracellular vesicles carrying pTau217 for Alzheimer's disease diagnosis and differential diagnosis.

Guo Z, Tian C, Shi Y, Song X, Yin W, Tao Q Acta Neuropathol Commun. 2024; 12(1):38.

PMID: 38444036 PMC: 10913681. DOI: 10.1186/s40478-024-01727-w.

Glycans in spent embryo culture medium are related to the implantation ability of blastocysts.

Wang D, Zhao Z, Xue X, Shi J, Shi W Heliyon. 2023; 9(5):e16255.

PMID: 37229168 PMC: 10205493. DOI: 10.1016/j.heliyon.2023.e16255.

PKM2-mediated neuronal hyperglycolysis enhances the risk of Parkinson's disease in diabetic rats.

Zhao Y, Wang Y, Wu Y, Tao C, Xu R, Chen Y J Pharm Anal. 2023; 13(2):187-200.

PMID: 36908857 PMC: 9999299. DOI: 10.1016/j.jpha.2022.11.006.

References

DAscenzo M, Choe L, Lee K . iTRAQPak: an R based analysis and visualization package for 8-plex isobaric protein expression data. Brief Funct Genomic Proteomic. 2008; 7(2):127-35. DOI: 10.1093/bfgp/eln007. View

Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U . Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2003; 249 Suppl 3:III/1-5. DOI: 10.1007/s00415-002-1301-4. View

Rademaker G, Pergantis S, Blok-Tip L, Langridge J, Kleen A, Thomas-Oates J . Mass spectrometric determination of the sites of O-glycan attachment with low picomolar sensitivity. Anal Biochem. 1998; 257(2):149-60. DOI: 10.1006/abio.1997.2548. View

Silveyra M, Cuadrado-Corrales N, Marcos A, Barquero M, Rabano A, Calero M . Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. J Neurochem. 2005; 96(1):97-104. DOI: 10.1111/j.1471-4159.2005.03514.x. View

Levin Y, Schwarz E, Wang L, Leweke F, Bahn S . Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J Sep Sci. 2007; 30(14):2198-203. DOI: 10.1002/jssc.200700189. View

Pan S, Zhang H, Rush J, Eng J, Zhang N, Patterson D . High throughput proteome screening for biomarker detection. Mol Cell Proteomics. 2005; 4(2):182-90. DOI: 10.1074/mcp.M400161-MCP200. View

Tan E, Skipper L . Pathogenic mutations in Parkinson disease. Hum Mutat. 2007; 28(7):641-53. DOI: 10.1002/humu.20507. View

Williams-Gray C, Foltynie T, Brayne C, Robbins T, Barker R . Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007; 130(Pt 7):1787-98. DOI: 10.1093/brain/awm111. View

Nagata Y, Burger M . Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. J Biol Chem. 1974; 249(10):3116-22. View

10.

Hanisch F, Jovanovic M, Peter-Katalinic J . Glycoprotein identification and localization of O-glycosylation sites by mass spectrometric analysis of deglycosylated/alkylaminylated peptide fragments. Anal Biochem. 2001; 290(1):47-59. DOI: 10.1006/abio.2000.4955. View

11.

Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C . Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res. 2007; 7(1):386-99. DOI: 10.1021/pr070501k. View

12.

Krokhin O, Ens W, Standing K, Wilkins J, Perreault H . Site-specific N-glycosylation analysis: matrix-assisted laser desorption/ionization quadrupole-quadrupole time-of-flight tandem mass spectral signatures for recognition and identification of glycopeptides. Rapid Commun Mass Spectrom. 2004; 18(18):2020-30. PMC: 7169070. DOI: 10.1002/rcm.1585. View

13.

Irungu J, Go E, Zhang Y, Dalpathado D, Liao H, Haynes B . Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. J Am Soc Mass Spectrom. 2008; 19(8):1209-20. PMC: 3706080. DOI: 10.1016/j.jasms.2008.05.010. View

14.

Zhang H, Li X, Martin D, Aebersold R . Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003; 21(6):660-6. DOI: 10.1038/nbt827. View

15.

Waragai M, Wei J, Fujita M, Nakai M, Ho G, Masliah E . Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun. 2006; 345(3):967-72. DOI: 10.1016/j.bbrc.2006.05.011. View

16.

Kurogochi M, Nishimura S . Structural characterization of N-glycopeptides by matrix-dependent selective fragmentation of MALDI-TOF/TOF tandem mass spectrometry. Anal Chem. 2004; 76(20):6097-101. DOI: 10.1021/ac049294n. View

17.

Dube D, Bertozzi C . Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005; 4(6):477-88. DOI: 10.1038/nrd1751. View

18.

Gendler S, Spicer A . Epithelial mucin genes. Annu Rev Physiol. 1995; 57:607-34. DOI: 10.1146/annurev.ph.57.030195.003135. View

19.

Wenk G . Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003; 64 Suppl 9:7-10. View

20.

Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds G, Jellinger K . Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989; 52(2):515-20. DOI: 10.1111/j.1471-4159.1989.tb09150.x. View